Bisphosphonates and periodontics: Potential applications for regulations of bone mass in the periodontium and other therapeutic/diagnostic uses

Journal of Periodontology

Volumn 73, Issue 7, 2002, Pages 813-822

  Tenenbaum, Howard C ^a   Shelemay, Avi ^a   Girard, Bruno ^a   Zohar, Ron ^a   Fritz, Peter C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bisphosphonates; Bone regeneration; Etidronate therapeutic use; Osteoblasts; Periondontal disease prevention and control

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; PYROPHOSPHATE; TILUDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE DEFECT; BONE DEVELOPMENT; BONE MASS; BONE METABOLISM; CELL ACTIVITY; CELL DIFFERENTIATION; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; METABOLIC BONE DISEASE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PERIODONTAL DISEASE; PERIODONTICS; PERIODONTIUM; REGENERATION; TOOTH IMPLANTATION;

ALENDRONATE; ALVEOLAR BONE LOSS; ANIMALS; BONE DENSITY; BONE REGENERATION; DIPHOSPHONATES; ETIDRONIC ACID; HUMANS; PERIODONTITIS;

EID: 0036045801     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2002.73.7.813     Document Type: Article

References (80)

1. The bacterial etiology of destructive periodontal disease: Current concepts
2. Long-term effect of surgical and non-surgical periodontal treatment. A 5-year clinical study
3. Long-term effect on surgical/non-surgical treatment of periodontal disease
4. The use of metronidazole and amoxicillin in the treatment of advanced periodontal disease. A prospective, controlled clinical trial
5. Repeated metronidazole and amoxicillin treatment of periodontitis. A follow-up study
6. Metronidazole in periodontitis: Reduced need for surgery
7. Adjunctive use of a subgingival controlled-release chlorhexidine chip reduces probing depth and improves attachment level compared with scaling and root planing alone
8. Cigar, pipe, and cigarette smoking as risk factors for periodontal disease and tooth loss
9. Evidence for cigarette smoking as a major risk factor for periodontitis
10. The significance of maintenance care in the treatment of periodontal disease
11. Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases
12. Non-steroidal anti-inflammatory drugs in the reduction of human alveolar bone loss
13. Flurbiprofen treatment of periodontal disease in beagles
14. Flurbiprofen treatment of human periodontitis: Effect on alveolar bone height and metabolism
15. Modulation of matrix metallo-proteinase activities in periodontitis as a treatment strategy
16. Randomized controlled trials of doxycycline in the prevention of recurrent periodontitis in high-risk patients: Antimicrobial activity and collagenase inhibition
17. Bisphosphonate modulates proliferation and differentiation of rat periodontal ligament cells during wound healing
18. Mechanisms of action of bisphosphonates
19. Cellular and molecular mechanisms of action of bisphosphonates
20. Regulation of alkaline phosphatase: Implications for calcium pyrophosphate dihydrate crystal dissolution and other alkaline phosphatase functions
21. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
22. Effects of bisphosphonate on isolated rat osteoclasts as examined by reflected light microscopy
23. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow
24. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
25. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces
26. MMP inhibition and downregulation by bisphosphonates
27. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models
28. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
29. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro
30. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes
31. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum
32. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages
33. Effects of bisphosphonates APD and HEBP on bone metabolism in vitro
34. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro
35. Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria
36. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells
37. Mechanisms of action of the bisphosphonates
38. Bisphosphonates: Mechanisms of action and clinical use in osteoporosis-an update
39. Bisphosphonates-preclinical
40. Effect of oral alendronate on bone mineral density and incidence of fractures in postmenopausal osteoporosis
41. Prevention of hip fractures in older women: A population-based perspective
42. Understanding the Bone Mass Measurement Act
43. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
44. Therapy of metastatic bone pain
45. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone
46. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
47. Effects of a bisphosphonate on experimental periodontitis in monkeys
48. Parenteral disphosphonates for treating malignant hypercalcemia
49. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure
50. The acute-phase response after bisphosphonate administration
51. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate
52. Experimental basis for the use of bisphosphonates in Paget's disease of bone
53. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys
54. Alendronate treatment of naturally occurring periodontitis in beagle dogs
55. Regional accelerated phenomenon (RAP) in the mandible following mucoperiosteal flap surgery
56. Studies in the alteration of vestibular depth
57. Histologic study of cellular mobilization and repair following a periosteal retention operation via split thickness mucogingival flap surgery
58. The effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats
59. Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats
60. Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats
61. Clinical, radiographic and scintigraphic findings in experimental periodontal disease in dogs
62. Predicting alveolar bone loss in beagles using bone-seeking radio-pharmaceutical uptake
63. Tetracycline treatment of periodontal disease in the beagle dog
64. Bone-seeking radiopharmaceutical uptake as an indicator of active alveolar bone loss in untreated and surgically treated teeth in beagle dogs
65. Autoradiographic localization of technetium-99 methylene diphosphonate in growth sites of young mice
66. Detection of active alveolar bone destruction in human periodontal disease by analysis of radiopharmaceutical uptake after a single injection of 99m-Tc-methylene diphosphonate
67. Nuclear medicine techniques for the detection of active alveolar bone loss
68. Detection of periodontal disease activity with a scintillation camera
69. Technetium 99m-MDP scintigraphy of patients undergoing implant prosthetic procedures: A follow-up study
70. Nuclear medicine: An indicator of "active" alveolar bone loss in beagle dogs treated with a non-steroidal anti-inflammatory drug
71. Flurbiprofen treatment of human periodontitis: Effect on alveolar bone height and metabolism
72. Prospective use of bisphosphonates in osteoporosis
73. Metabolism of phosphonates
74. An ultrastructural study of osteogenesis in chick periosteum in vitro
75. The regulatory effect of phosphates on bone metabolism in vitro
76. Osteogenic phase-specific co-regulation of collagen synthesis and mineralization by β-glycerophosphate in chick periosteal cultures
77. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
78. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
79. Backscattered electron image assessment of mineral density in bone formed in vitro
80. Ankylosis of the mouse molar after systemic administration of 1-hydroxyethylindene-1, 1-bisphosphonate (HEBP)